About Methylomics

Methylomics is a start-up company that applies state of the art methylation sequencing technology (MeD-seq) for diagnosis and classification of cancer as well as disease progression and therapy response monitoring. With a multidisciplinary team of top scientists, we construct a DNA methylation atlas of different tissues and associated cancers. Methylomics developed in-house bioinformatic algorithms to rapidly discover differentially methylated regions for specific cancer types. We aim to generate a database that can be used for the diagnosis, as well as the determination of the origin, of all cancer types.

In addition to marker discovery and direct classification of cancers we use the marker profiles generated by our MeD-seq technology as a basis for the development of fast and low-cost methylation assays. Because of our streamlined bioinformatic process to select these markers and design assays, Methylomics is rapidly expanding its pipeline, now including cancers of the colorectal region, skin, head & neck, anus, and uro-genital zone (e.g., cervical, ovarian, vulva and endometrial cancers).

Methylomics discovered two proprietary pan-gynecological markers and developed a MeD-Scan assay for the rapid detection of all types of gynecological cancer. Three validation studies, showing the remarkably high sensitivity of this MeD-Scan assay, will be published in Q1 2024, along with the patent application for these markers.

A novel method to detect DNA methylation genome wide

Developed by the founders Methylomics, Methylated DNA Sequencing (MeD-seq) offers a cutting-edge approach for genome-wide methylation profiling. The distinguishing feature of our sequencing technology is the utilization of a methylation-dependent restriction enzyme. When this enzyme digests DNA, it generates small fragments containing methylated CpG sites. These fragments are then isolated and prepared for Next Generation Sequencing. What sets MeD-seq apart is its ability to explore nearly half of the CpG sites in the human genome. Unlike alternative methods, like bisulfite sequencing and array platforms, MeD-seq eliminates the need for DNA bisulfite conversion, facilitating unbiased genome-wide DNA methylation profiling. Because of the omission of the DNA-damaging bisulfite conversion step, the minimal required DNA input is significantly lower compared to other methods. This property makes MeD-seq highly compatible with applications such as Laser Capture Microdissection (LCM), liquid biopsy samples (such as cell-free DNA), and small populations of FACS-sorted cell types. Given that MeD-seq exclusively sequences methylated DNA, it's been demonstrated to yield comprehensive DNA methylation data at significantly lower costs when compared to alternative techniques.

The MeD-seq technology can be used for the diagnosis of cancers and other diseases, as a marker discovery tool and basis for the development of rapid diagnostic assays, and for the monitoring of treatment outcomes.

Profiling DNA Methylation genome wide

Transformation of healthy cells into cancer cells coincides with massive changes in genome wide DNA methylation. MeD-seq is applied to detect DNA methylation profiles of healthy tissues and (pre-) cancerous lesions and has already been compared to other techniques.

read more

Methylation marker discovery for specific cancers and cancer subgroups

With the sequencing data from MeD-seq we construct genome-wide DNA methylation profiles for normal and diseased tissue types to develop cancer detection markers.

read more

Target DNA enrichment using Laser Capture Microdissection

Laser Capture Microdissection (LCM) is an accurate method to select and isolate specific cell populations from heterogeneous archived paraffine embedded tissue for further downstream genome-wide DNA methylation profiling.

read more

MeD-seq: Pushing down the limit of DNA required

MeD-seq requires a relatively low amount of DNA, making it compatible with a range of applications like cell free DNA and Laser Capture Micro dissected DNA samples. Efforts are undertaken to push MeD-seq towards the single cell level.

read more

Wim H. Quint

Chief Executive Officer

Wim is the CEO of Methylomics. He received his PhD in genetics from the Erasmus University. Wim oversees the primary processes, the acquisition of new projects and funding opportunities. He also manages collaborations with academic and industrial partners.


Joost Gribnau

Senior Scientific Advisor

Prof. dr. Gribnau is member of the Scientific Advisory Board of Methylomics. He is the head of the department of Developmental Biology at the Erasmus MC and an EMBO member and recipient of numerous prizes/awards, including the prestigious VICI and ERC grants, as well as the Huygens Descartes prize. He and his laboratory developed the MeD-seq technology.

    Wilfred van IJcken

    Scientific Advisor

    Wilfred is a founder and member of the Scientific Advisory Board of Methylomics. Wilfred studied Molecular Sciences at the Wageningen University and Research center and received a Ph.D. in Virology at the same university. He is a genomics expert and published more than 220 scientific papers in peer reviewed international journals.

    Ruben Boers

    Advisor Biotechnology & Development

    Ruben is a founder and the Biotechnology & development advisor of the Scientific Advisory board. Ruben is responsible for analyzing the sequencing data and development of MeD-seq.





    Joachim Boers

    Advisor Bioinformatics & Development

    Joachim is a founder and Bioinformatics & Development advisor of the Scientific Advisory Board. Joachim is responsible for the software developed by Methylomics.





    Henk van den Munckhof

    Process Coordinator


    Henk is the process coordinator at Methylomics. Henk leads all laboratory processes including the set-up of new projects and data analysis.







      Wim Quint †

      Founder


      Wim was one of the founders of Methylomics. He received a Ph.D. in biochemistry for the University of Nijmegen. He was specialized in molecular diagnostics of infectious diseases and was a key opinion leader on the human papillomavirus research. Wim had published more than 450 papers in international scientific journals. Wim has passed away in July 2023.

        Kirke Tadema

        Senior Research Technician &
        General Support Officer

        Frederique Prevoo

        Research Technician

        Lotte Martens

        Research Technician

        error: Content is protected !!